Clinical Trials Browser

Phase 2 × Muscle-Invasive Bladder Carcinoma × spartalizumab × Clear all

NCT04909775 2021-06-02

Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer

Phase 2 Unknown

Muscle-Invasive Bladder Carcinoma